Amendments to the Claims:

1. (Currently Amended) A sustained release oral matrix tablet ~~dosage form~~ comprising~~:~~

~~a single functional layer; and~~

~~optionally, one or more nonfunctional layers adjacent to the single functional layer,~~

~~wherein the single functional layer comprises~~ alfuzosin or pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof, and ~~one or more~~ a release-retarding agent~~ingredients~~ comprises in combination hydroxypropylmethyl cellulose and hydroxypropyl cellulose.

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Currently Amended) The sustained release tablet~~dosage form~~ of claim 1, wherein the tablet~~single functional layer~~ further comprises one or more pharmaceutically acceptable excipients.

6. (Currently Amended) The sustained release tablet~~oral dosage form~~ of claim ~~1~~5, wherein the one or more pharmaceutically acceptable excipients comprise one or more of binders, diluents, and lubricants/glidants.

7. (Currently Amended) The sustained release tablet~~oral dosage form~~ of claim 6, wherein the binders comprise one or more of polyvinyl pyrrolidone, pregelatinized starch, and gelatin.

8. (Currently Amended) The sustained release tablet~~oral dosage form~~ of claim 6, wherein the diluents comprise one or more of lactose, mannitol, and microcrystalline cellulose.

9. (Currently Amended) The sustained release tablet~~oral dosage form~~ of claim 6, wherein the lubricants comprise one or more of magnesium stearate, zinc stearate, talc, and colloidal silicon dioxide.

10. (Currently Amended) The sustained release tablet~~oral dosage form~~ of claim 1, wherein the tablet ~~functional layer~~ comprises between about 10% to about 90% w/w of hydroxypropyl methylcellulose and between about 10% to about 90% w/w of hydroxypropyl cellulose.

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Currently Amended) The sustained release tablet~~oral dosage form~~ of claim 1, further comprising~~wherein the~~ one or more nonfunctional layers surrounding the tablet~~adjacent to the single functional layer comprises a cosmetic coating~~.

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Currently Amended) A process for forming a sustained release oral matrix tabletdosage form, the process comprising:

forming a mixture of alfuzosin or pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof and aone or more release-retarding agent comprisingingredients;

compressing the mixture into a tabletforming a dosage form having a single functional layer from the mixture; and

optionally coating the tablet withforming one or more nonfunctional layers adjacent to the single functional layer.

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35. (Currently Amended l) The process of claim 29, wherein theforming a mixture is granulated byeomprises one or more of direct compression, wet granulation or, and dry granulation.

36. (Cancelled)

37. (Currently Amended) The process of claim 29, wherein forming a mixture further comprises adding one or more pharmaceutically acceptable excipients to the mixture.

38. (Cancelled)

39. (Cancelled)

40. (Cancelled)